Analytical Data
-
Gene name
GAGE10
- Application
-
Alternative Names
GAGE10G antigen 10; GAGE-10
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A6NGK3
-
Expression Region
1-116aa
-
AA Sequence
MSWRGRSTYRSRPRLYVEPPEMIGPMLPEQFSDEVEPATPEEGEPATQRQDPAAAQEGEDEGASAGQGPKPEADSQEQVHPKTGCECGDGPDGQEMGLPNPEEVKRPEEGEKQSQC
-
Molecular Weight
12.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of GAGE10 recombinant protein is rooted in the exploration of cancer immunology and the potential for targeted therapies. GAGE10 is a member of the GAGE family of cancer/testis antigens, which are aberrantly expressed in various tumors but not in normal tissues, making them promising candidates for cancer immunotherapy. These proteins are typically presented on the surface of cancer cells, recognized by the immune system's T-cells, suggesting that they could be leveraged to develop effective cancer vaccines or adoptive T-cell therapies. Recent research has focused on the molecular characterization of GAGE10, its role in tumorigenesis, and its interaction with immune cells. By generating GAGE10 recombinant proteins, researchers aim to evaluate their immunogenicity and potential for eliciting T-cell responses in vitro and in vivo. This work not only enhances the understanding of tumor immunology but also paves the way for personalized cancer treatments by harnessing the body's immune system to recognize and attack malignant cells. As the field of cancer immunotherapy advances, the study of GAGE10 could contribute significantly to developing novel strategies for treating malignancies, particularly those resistant to conventional therapies.
